Zanubrutinib Monotherapy in Patients With Del(17p) and Treatment-Naive CLL/SLL (SEQUOIA Arm C)
September 29th 2025Experts discuss the critical role of biomarker testing in guiding frontline treatment decisions for chronic lymphocytic leukemia (CLL)—especially in high-risk patients with TP53 mutations or deletion 17p—and highlight promising 5-year outcomes from the SEQUOIA trial, which supports targeted monotherapy as an effective alternative to chemoimmunotherapy in this population.